{
  "id": "be1295dc830a",
  "type": "finding",
  "topic": "Zepbound 2025 analyst estimates",
  "summary": "Early 2025 analyst consensus: Full-year 2025 Zepbound sales ~$10.39B, but this was conservative given Q3 2025 already hit $9.28B YTD",
  "content": "From CNBC article (Feb 2025):\n- FactSet analysts predicted Zepbound 2025 sales of $10.39 billion (more than double from 2024)\n- However, Q1-Q3 2025 actual YTD was $9,281.4M, already exceeding 89% of this estimate\n- Analyst consensus was too conservative\n- Analysts also predicted Mounjaro 2025 sales of $18.17 billion\n\n2024 actual Zepbound full year: ~$4,925.7M (sum of quarterly figures)\nImplied Q4 2025 if $10.39B full year target: ~$1,108M (clearly too low given Q3 was $3,588M)",
  "sources": [
    "https://cnbc.com/2025/02/05/eli-lilly-earnings-lly-will-zepbounds-growth-live-up-to-the-hype.html"
  ],
  "confidence": 0.8,
  "question_id": 41517,
  "report_path": "",
  "created_at": "2026-02-07T03:30:58.394052Z"
}